Australian Government

Department of Health and Ageing

SCHEDULE OF PHARMACEUTICAL BENEFITS

SUMMARY OF CHANGES

EFFECTIVE 1 OCTOBER 2009

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 October 2009. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 October 2009 and are included, where applicable, in prices published in the Schedule—

Dispensing Fees:	Ready-prepared	$6.42
	Dangerous drug fee	$2.71
	Extemporaneously-prepared	$8.46
	Allowable additional patient charge*	$3.79
Additional Fees (for safety net prices):	Ready-prepared	$1.05
	Extemporaneously-prepared	$1.38
Patient Co-payments:	General	$32.90
	Concessional	$5.30
Safety Net Thresholds:	General	$1264.90
	Concessional	$318.00
Safety Net Card Issue Fee:		$8.25

*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

SUMMARY OF CHANGES

ADDITIONS

Additions — Brands

8118G *Alprazolam-GA, GM* — **Alprazolam**, Tablet 2 mg

8596K *Sulprix, AF* — **Amisulpride**, Tablet 400 mg
8220P *Citalopram generichealth, GQ* — **Citalopram hydrobromide**, Tablet 20 mg (base)
8505P *APO-Gabapentin, TX* — **Gabapentin**, Capsule 100 mg
8331L *Ozmep, ZP* — **Omeprazole**, Tablet 20 mg
8333N *Ozmep, ZP* — **Omeprazole**, Tablet 20 mg **(Diff. Max. Rpts)**
8539K *Oxaliplatin Alphapharm, AF* — **Oxaliplatin**, Powder for I.V. infusion 50 mg
8540L *Oxaliplatin Alphapharm, AF* — **Oxaliplatin**, Powder for I.V. infusion 100 mg
2011W *Simvastatin-GA 10, GN* — **Simvastatin**, Tablet 10 mg
9242K *Simvastatin-GA 10, GN* — **Simvastatin**, Tablet 10 mg **(Diff. Max. Rpts)**
8163P *APO-Topiramate, TX; Tamate, AF; Topiramate Sandoz, SZ* — **Topiramate**, Tablet 25 mg
8164Q *APO-Topiramate, TX; Tamate, AF; Topiramate Sandoz, SZ* — **Topiramate**, Tablet 50 mg
8165R *APO-Topiramate, TX; Tamate, AF; Topiramate Sandoz, SZ* — **Topiramate**, Tablet 100 mg

8166T *APO-Topiramate, TX; Tamate, AF; Topiramate Sandoz, SZ* — **Topiramate**, Tablet 200 mg

Additions — Bioequivalence Indicators

The bioequivalence indicator ([a]) has been added to the following brands:

8163P *Topamax, JC* — **Topiramate**, Tablet 25 mg

8164Q *Topamax, JC* — **Topiramate**, Tablet 50 mg
8165R *Topamax, JC* — **Topiramate**, Tablet 100 mg

8166T *Topamax, JC* — **Topiramate**, Tablet 200 mg

DELETIONS

Deletions — Items

3072Q **Amino acid formula without phenylalanine**, Powder 250 g (*PK AID II*)

1752F **Naloxone hydrochloride**, Injection 800 micrograms in 2 mL (*Naloxone Min-I-Jet*)
3481F **Naloxone hydrochloride**, Injection 800 micrograms in 2 mL (*Naloxone Min-I-Jet*) **(Doctor's Bag)**

5174H **Naloxone hydrochloride**, Injection 800 micrograms in 2 mL (*Naloxone Min-I-Jet*) **(Dental)**

Deletions — Brands

3058Y *Sporahexal, HX* — **Cephalexin**, Capsule 250 mg

3317N *Sporahexal, HX* — **Cephalexin**, Capsule 250 mg **(Dental)**
3119E *Sporahexal, HX* — **Cephalexin**, Capsule 500 mg
3318P *Sporahexal, HX* — **Cephalexin**, Capsule 500 mg **(Dental)**
1299J *Dinac, GM* — **Diclofenac sodium**, Tablet 25 mg (enteric coated)
5364H *Dinac, GM* — **Diclofenac sodium**, Tablet 25 mg (enteric coated) **(Palliative Care)**
5361E *Dinac, GM* — **Diclofenac sodium**, Tablet 25 mg (enteric coated) **(Palliative Care) (Diff. Max. Rpts)**
5076E *Dinac, GM* — **Diclofenac sodium**, Tablet 25 mg (enteric coated) **(Dental)**
1834M *Pendine 300, AL* — **Gabapentin**, Capsule 300 mg

2449X *Diamicron, SE* — **Gliclazide**, Tablet 80 mg

ALTERATIONS

Alterations — Proprietary Name

From:

9397N **Amino acid formula with vitamins and minerals without phenylalanine**, Oral liquid 62.5 mL, 60 (*Lophlex LQ 10*)

To:

9397N **Amino acid formula with vitamins and minerals without phenylalanine**, Oral liquid 62.5 mL, 60 (*PKU Lophlex LQ 10*)

From:

9021T **Amino acid formula with vitamins and minerals without phenylalanine**, Oral liquid 125 mL, 30 (*Lophlex LQ*)

To:

9021T **Amino acid formula with vitamins and minerals without phenylalanine**, Oral liquid 125 mL, 30 (*PKU Lophlex LQ 20*)

Alterations — Manufacturer's Code

		From	*To*
8118G	**Alprazolam**, Tablet 2 mg (*Alprazolam-DP*)	GM	GN
1891M	**Amoxycillin with clavulanic acid**, Tablet 500 mg-125 mg (*Moxiclav Duo 500/125*)	AW	SI
5008N	**Amoxycillin with clavulanic acid**, Tablet 500 mg-125 mg (*Moxiclav Duo 500/125*) **(Dental)**	AW	SI
8254K	**Amoxycillin with clavulanic acid**, Tablet 875 mg-125 mg (*Moxiclav Duo Forte 875/125*)	AW	SI
5006L	**Amoxycillin with clavulanic acid**, Tablet 875 mg-125 mg (*Moxiclav Duo Forte 875/125*) **(Dental)**	AW	SI
2460L	**Cefaclor**, Powder for oral suspension 125 mg per 5 mL, 100 mL (*Aclor 125*)	AW	SI
5046N	**Cefaclor**, Powder for oral suspension 125 mg per 5 mL, 100 mL (*Aclor 125*) **(Dental)**	AW	SI
2461M	**Cefaclor**, Powder for oral suspension 250 mg per 5 mL, 75 mL (*Aclor 250*)	AW	SI
5047P	**Cefaclor**, Powder for oral suspension 250 mg per 5 mL, 75 mL (*Aclor 250*) **(Dental)**	AW	SI
1299J	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Clonac 25*)	AW	SI
1299J	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Diclofenac-GA*)	GN	GM
5364H	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Clonac 25*) **(Palliative Care)**	AW	SI
5364H	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Diclofenac-GA*) **(Palliative Care)**	GN	GM
5361E	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Clonac 25*) **(Palliative Care) (Diff. Max. Rpts)**	AW	SI
5361E	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Diclofenac-GA*) **(Palliative Care) (Diff.Max.Rpts)**	GN	GM
5076E	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Clonac 25*) **(Dental)**	AW	SI
5076E	**Diclofenac sodium**, Tablet 25 mg (enteric coated) (*Diclofenac-GA*) **(Dental)**	GN	GM
1300K	**Diclofenac sodium**, Tablet 50 mg (enteric coated) (*Clonac 50*)	AW	SI
5365J	**Diclofenac sodium**, Tablet 50 mg (enteric coated) (*Clonac 50*) **(Palliative Care)**	AW	SI
5362F	**Diclofenac sodium**, Tablet 50 mg (enteric coated) (*Clonac 50*) **(Palliative Care) (Diff. Max. Rpts)**	AW	SI
5077F	**Diclofenac sodium**, Tablet 50 mg (enteric coated) (*Clonac 50*) **(Dental)**	AW	SI
3064G	**Lactulose**, Mixture 3.34 g per 5 mL, 500 mL (*Genlac*)	AW	SI
5388N	**Lactulose**, Mixture 3.34 g per 5 mL, 500 mL (*Genlac*) **(Palliative Care)**	AW	SI
5387M	**Lactulose**, Mixture 3.34 g per 5 mL, 500 mL (*Genlac*) **(Palliative Care) (Diff. Max. Rpts)**	AW	SI
2011W	**Simvastatin**, Tablet 10 mg (*Simvar 10*)	AW	SI
9242K	**Simvastatin**, Tablet 10 mg (*Simvar 10*) **(Diff. Max. Rpts)**	AW	SI
2012X	**Simvastatin**, Tablet 20 mg (*Simvar 20*)	AW	SI
9243L	**Simvastatin**, Tablet 20 mg (*Simvar 20*) **(Diff. Max. Rpts)**	AW	SI
8173E	**Simvastatin**, Tablet 40 mg (*Simvar 40*)	AW	SI

9244M	**Simvastatin**, Tablet 40 mg (*Simvar 40*) **(Diff. Max. Rpts)**	AW	SI
8313M	**Simvastatin**, Tablet 80 mg (*Simvar 80*)	AW	SI
9245N	**Simvastatin**, Tablet 80 mg (*Simvar 80*) **(Diff. Max. Rpts)**	AW	SI
8455B	**Tramadol hydrochloride**, Capsule 50 mg (*Zydol*)	AW	SI
8611F	**Tramadol hydrochloride**, Capsule 50 mg (*Zydol*) **(Diff. Max. Rpts)**	AW	SI
5232J	**Tramadol hydrochloride**, Capsule 50 mg (*Zydol*) **(Dental)**	AW	SI
8523N	**Tramadol hydrochloride**, Tablet 100 mg (twice daily sustained release) (*Zydol SR 100*)	AW	SI
5234L	**Tramadol hydrochloride**, Tablet 100 mg (twice daily sustained release) (*Zydol SR 100*) **(Dental)**	AW	SI
8524P	**Tramadol hydrochloride**, Tablet 150 mg (twice daily sustained release) (*Zydol SR 150*)	AW	SI
5235M	**Tramadol hydrochloride**, Tablet 150 mg (twice daily sustained release) (*Zydol SR 150*) **(Dental)**	AW	SI
8525Q	**Tramadol hydrochloride**, Tablet 200 mg (twice daily sustained release) (*Zydol SR 200*)	AW	SI
5236N	**Tramadol hydrochloride**, Tablet 200 mg (twice daily sustained release) (*Zydol SR 200*) **(Dental)**	AW	SI

Alterations — Restrictions

(see under 'RESTRICTIONS' below for full details)

2387P	**Methylphenidate hydrochloride**, Tablet 18 mg (extended release) (*Concerta*)
2172H	**Methylphenidate hydrochloride**, Tablet 27 mg (extended release) (*Concerta*)
2388Q	**Methylphenidate hydrochloride**, Tablet 36 mg (extended release) (*Concerta*)
2432B	**Methylphenidate hydrochloride**, Tablet 54 mg (extended release) (*Concerta*)
2276T	**Methylphenidate hydrochloride**, Capsule 20 mg (modified release) (*Ritalin LA*)
2280B	**Methylphenidate hydrochloride**, Capsule 30 mg (modified release) (*Ritalin LA*)
2283E	**Methylphenidate hydrochloride**, Capsule 40 mg (modified release) (*Ritalin LA*)

Removal of restrictions

The following items are now unrestricted benefits:

8286D	**Oestradiol**, Transdermal gel 1 mg in 1 g sachet, 28 (*Sandrena*)
8761D	**Oestradiol**, Transdermal patches 390 micrograms (releasing approximately 25 micrograms per 24 hours), 8 (*Estradot 25*)
8311K	**Oestradiol**, Transdermal patches 750 micrograms (releasing approximately 25 micrograms per 24 hours), 8 (*Estraderm MX 25*)
8485N	**Oestradiol**, Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 4 (*Climara 25*)
1743R	**Oestradiol**, Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 8 (*Estraderm 25*)
8762E	**Oestradiol**, Transdermal patches 585 micrograms (releasing approximately 37.5 micrograms per 24 hours), 8 (*Estradot 37.5*)
8140K	**Oestradiol**, Transdermal patches 1.5 mg (releasing approximately 50 micrograms per 24 hours), 8 (*Estraderm MX 50*)
8125P	**Oestradiol**, Transdermal patches 3.8 mg (releasing approximately 50 micrograms per 24 hours), 4 (*Climara 50*)
1744T	**Oestradiol**, Transdermal patches 4 mg (releasing approximately 50 micrograms per 24 hours), 8 (*Estraderm 50*)
8763F	**Oestradiol**, Transdermal patches 780 micrograms (releasing approximately 50 micrograms per 24 hours), 8 (*Estradot 50*)
8486P	**Oestradiol**, Transdermal patches 5.7 mg (releasing approximately 75 micrograms per 24 hours), 4 (*Climara 75*)
8764G	**Oestradiol**, Transdermal patches 1.17 mg (releasing approximately 75 micrograms per 24 hours), 8 (*Estradot 75*)

8312L **Oestradiol**, Transdermal patches 3 mg (releasing approximately 100 micrograms per 24 hours), 8 (*Estraderm MX 100*)

8126Q **Oestradiol**, Transdermal patches 7.6 mg (releasing approximately 100 micrograms per 24 hours), 4 (*Climara 100*)

1745W **Oestradiol**, Transdermal patches 8 mg (releasing approximately 100 micrograms per 24 hours), 8 (*Estraderm 100*)

8765H **Oestradiol**, Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8 (*Estradot 100*)

8427M **Oestradiol with norethisterone acetate**, Transdermal patches 620 micrograms-2.7 mg (releasing approximately 50 micrograms- 140 micrograms per 24 hours), 8 (*Estalis continuous 50/140*)

8428N **Oestradiol with norethisterone acetate**, Transdermal patches 510 micrograms-4.8 mg (releasing approximately 50 micrograms- 250 micrograms per 24 hours), 8 (*Estalis continuous 50/250*)

8425K **Oestradiol and oestradiol with norethisterone acetate**, Pack containing 4 transdermal patches oestradiol 780 micrograms (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 620 micrograms-2.7 mg (releasing approximately 50 micrograms-140 micrograms per 24 hours) (*Estalis sequi 50/140*)

8426L **Oestradiol and oestradiol with norethisterone acetate**, Pack containing 4 transdermal patches oestradiol 780 micrograms (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 510 micrograms-4.8 mg (releasing approximately 50 micrograms-250 micrograms per 24 hours) (*Estalis sequi 50/250*)

8029N **Oestradiol and oestradiol with norethisterone acetate**, Pack containing 4 transdermal patches oestradiol 4 mg (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 10 mg-30 mg (releasing approximately 50 micrograms- 250 micrograms per 24 hours) (*Estracombi*)

SECTION 100

HIGHLY SPECIALISED DRUGS PROGRAM

DELETIONS

Deletions — Items

6487K **Epoetin beta**, Injection 30,000 units in 0.6 mL pre-filled syringe (*NeoRecormon*)

6344X **Indinavir sulfate**, Capsule 100 mg (base) (*Crixivan 100 mg*)

6201J **Indinavir sulfate**, Capsule 200 mg (base) (*Crixivan 200 mg*)

6393L **Ribavirin and peginterferon alfa-2a**, Pack containing 84 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms (*Pegasys RBV*)

ALTERATIONS

Alterations — Restrictions

(see under 'RESTRICTIONS' below for full details)

6126K **Filgrastim**, Injection 300 micrograms in 1 mL (*Neupogen*)

6291D **Filgrastim**, Injection 300 micrograms in 0.5 mL single use pre-filled syringe (*Neupogen*)

6127L **Filgrastim**, Injection 480 micrograms in 1.6 mL (*Neupogen*)

6292E **Filgrastim**, Injection 480 micrograms in 0.5 mL single use pre-filled syringe (*Neupogen*)

6363X **Pegfilgrastim**, Injection 6 mg in 0.6 mL single use pre-filled syringe (*Neulasta*)

Alteration - Manufacturer's Code

		From	*To*
9622K	**Sitaxentan sodium**, Tablet 100 mg (*Thelin*)	CS	PF

ADVANCE NOTICES

Advance Notice — Deletion of Items

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 November 2009:
Items discontinued by the manufacturer—

2240X **Lansoprazole**, Capsule 30 mg (*Zoton*)

2241Y **Lansoprazole**, Capsule 30 mg (*Zoton*) **(Diff. Max. Rpts)**

Deletion requested by the manufacturer—

1251W **Terbutaline sulfate**, Nebuliser solution single dose units 5 mg in 2 mL, 30 (*Bricanyl Respules*)

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 January 2010:
Items discontinued by the manufacturer—

2737C **Amino acid formula with vitamins and minerals without phenylalanine**, Infant formula, powder 400 g (*XP Analog*)

8706F **Amino acid formula without phenylalanine**, Bars 42 g, 20 (*Phlexy-10*)

Advance Notice — Deletion of Brands

The following brands will be deleted from the Schedule of Pharmaceutical Benefits on 1 December 2009:
Brands discontinued by the manufacturer—

1157X *Tagamet, GK* — **Cimetidine**, Tablet 200 mg

8884N *Metex SR, SI* — **Metformin hydrochloride**, Tablet 500 mg (extended release)

1975Y *Quinsul, LN* — **Quinine sulfate**, Tablet 300 mg

The following brand will be deleted from the Schedule of Pharmaceutical Benefits on 1 January 2010:
Brand discontinued by the manufacturer—

8118G *Alprazolam-DP, GN* — **Alprazolam**, Tablet 2 mg

The following brand will be deleted from the Schedule of Pharmaceutical Benefits on 1 April 2010:
Brand discontinued by the manufacturer—

3012M *K-Sol, LN* — **Potassium chloride with potassium bicarbonate**, Effervescent tablet 14 mmol potassium and 8 mmol chloride

RESTRICTIONS

The text of restrictions mentioned above:

6291D **Filgrastim**, Injection 300 micrograms in 0.5 mL single use pre-filled syringe (*Neupogen*)

6126K **Filgrastim**, Injection 300 micrograms in 1 mL (*Neupogen*)

6292E **Filgrastim**, Injection 480 micrograms in 0.5 mL single use pre-filled syringe (*Neupogen*)

6127L **Filgrastim**, Injection 480 micrograms in 1.6 mL (*Neupogen*)

Private hospital authority required

For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia

Private hospital authority required

Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy

Private hospital authority required

Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation

Private hospital authority required

A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation

Private hospital authority required

A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation

Private hospital authority required

A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)

Private hospital authority required

A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))

Private hospital authority required

A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))

Private hospital authority required

A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

acute lymphoblastic leukaemia

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

germ cell tumours

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

infants and children with CNS tumours

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

neuroblastoma

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

relapsed Hodgkin disease

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

sarcoma

2276T **Methylphenidate hydrochloride**, Capsule 20 mg (modified release) (*Ritalin LA*)
2280B **Methylphenidate hydrochloride**, Capsule 30 mg (modified release) (*Ritalin LA*)
2283E **Methylphenidate hydrochloride**, Capsule 40 mg (modified release) (*Ritalin LA*)

NOTE:

Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride

Authority required

Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours

2387P **Methylphenidate hydrochloride**, Tablet 18 mg (extended release) (*Concerta*)
2172H **Methylphenidate hydrochloride**, Tablet 27 mg (extended release) (*Concerta*)
2388Q **Methylphenidate hydrochloride**, Tablet 36 mg (extended release) (*Concerta*)
2432B **Methylphenidate hydrochloride**, Tablet 54 mg (extended release) (*Concerta*)

NOTE:

Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride

Authority required

Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours

6363X **Pegfilgrastim**, Injection 6 mg in 0.6 mL single use pre-filled syringe (*Neulasta*)

Private hospital authority required

For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia

Private hospital authority required

A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification

for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

acute lymphoblastic leukaemia

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

germ cell tumours

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

infants and children with CNS tumours

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

neuroblastoma

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

relapsed Hodgkin disease

Private hospital authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in

sarcoma

REPATRIATION PHARMACEUTICAL BENEFITS

These changes to the Repatriation Pharmaceutical Benefits Schedule are effective from 1 October 2009. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

SUMMARY OF CHANGES

ADDITIONS

Additions — Bioequivalence Indicators

4175R *Alzene, AF; Zyrtec, JT* — **Cetirizine hydrochloride**, Tablet 10 mg